PROSTATE CANCER: Better VISTAs ahead? Potential and pitfalls of immunotherapy

    loading  Checking for direct PDF access through Ovid

Abstract

Despite a rapid increase in the use of anticancer immunotherapy, our understanding of the mechanisms of action and the patients’ responses remains limited. The discovery of immune inhibitory markers in the tumour microenvironment following immunotherapy should improve our understanding and might enable us to better apply combination therapies.

Refers to Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23, 551-555 (2017)

Related Topics

    loading  Loading Related Articles